Equities research analysts predict that Acadia Healthcare Company Inc (NASDAQ:ACHC) will post sales of $763.10 million for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Acadia Healthcare’s earnings, with the highest sales estimate coming in at $773.69 million and the lowest estimate coming in at $755.00 million. Acadia Healthcare posted sales of $716.71 million during the same quarter last year, which would indicate a positive year over year growth rate of 6.5%. The firm is expected to report its next quarterly earnings report after the market closes on Monday, November 5th.

On average, analysts expect that Acadia Healthcare will report full year sales of $3.04 billion for the current fiscal year, with estimates ranging from $3.03 billion to $3.06 billion. For the next year, analysts forecast that the firm will post sales of $3.22 billion, with estimates ranging from $3.18 billion to $3.29 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Acadia Healthcare.

Acadia Healthcare (NASDAQ:ACHC) last released its quarterly earnings data on Monday, July 30th. The company reported $0.70 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.70. Acadia Healthcare had a net margin of 7.52% and a return on equity of 7.93%. The firm had revenue of $765.70 million during the quarter, compared to analysts’ expectations of $767.93 million. During the same period in the previous year, the business posted $0.66 earnings per share. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year.

A number of brokerages have recently issued reports on ACHC. Jefferies Financial Group boosted their target price on shares of Acadia Healthcare from $44.00 to $47.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. Zacks Investment Research raised shares of Acadia Healthcare from a “hold” rating to a “buy” rating and set a $48.00 target price for the company in a research report on Tuesday, July 24th. Mizuho set a $37.00 target price on shares of Acadia Healthcare and gave the company a “hold” rating in a research report on Tuesday, August 28th. Craig Hallum cut shares of Acadia Healthcare from a “buy” rating to a “hold” rating in a research report on Wednesday, October 17th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $39.00 target price on shares of Acadia Healthcare in a research report on Thursday, October 18th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. Acadia Healthcare currently has an average rating of “Hold” and an average target price of $43.11.

ACHC stock traded up $0.92 during midday trading on Tuesday, reaching $39.50. 2,905,140 shares of the company were exchanged, compared to its average volume of 2,791,010. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.24 and a quick ratio of 1.24. Acadia Healthcare has a one year low of $26.92 and a one year high of $45.02. The stock has a market cap of $3.49 billion, a price-to-earnings ratio of 17.17, a price-to-earnings-growth ratio of 1.42 and a beta of 0.63.

Several institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN raised its stake in Acadia Healthcare by 52.4% in the first quarter. Wells Fargo & Company MN now owns 34,769 shares of the company’s stock valued at $1,362,000 after purchasing an additional 11,951 shares in the last quarter. Principal Financial Group Inc. raised its stake in Acadia Healthcare by 2.8% in the first quarter. Principal Financial Group Inc. now owns 356,158 shares of the company’s stock valued at $13,954,000 after purchasing an additional 9,548 shares in the last quarter. UBS Group AG raised its stake in Acadia Healthcare by 88.6% in the first quarter. UBS Group AG now owns 76,738 shares of the company’s stock valued at $3,007,000 after purchasing an additional 36,045 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Acadia Healthcare in the first quarter valued at about $255,000. Finally, Legal & General Group Plc raised its stake in Acadia Healthcare by 20.9% in the first quarter. Legal & General Group Plc now owns 93,441 shares of the company’s stock valued at $3,661,000 after purchasing an additional 16,126 shares in the last quarter.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities. The company operates acute inpatient psychiatric facilities, which offer evaluation and crisis stabilization of patients with severe psychiatric diagnoses; specialty treatment facilities, including residential recovery facilities, eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders; and residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs.

See Also: What is the Rule of 72?

Get a free copy of the Zacks research report on Acadia Healthcare (ACHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acadia Healthcare (NASDAQ:ACHC)

Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.